Adagene (ADAG) Reports FY22, Provides Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. MRVL
2. USO
3. SPY
4. OPCH
5. BBIO
6. NVDA
7. GOOGL
8. CHRW
9. AMD
10. STZ

Go back to Adagene (ADAG) Reports FY22, Provides Corporate Update

Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update

March 28, 2023 4:31 PM EDT

- Clinical data for wholly-owned anti-CTLA-4 franchise show best-in-class safety profiles for unmasked and masked candidates, unlocking the full therapeutic benefit of anti-CTLA-4 in combination with anti-PD-1 and beyond -

- Roche sponsoring randomized, multi-national phase 1b/2 trial of novel triple combination therapy in first-line liver cancer, leveraging safety profile of masked, anti-CTLA-4 SAFEbody® ADG126 -

- Sanofi and Exelixis collaborations present multi-billion dollar opportunity for non-dilutive funding via milestones and royalties -

- Cash balance of US$143.8 million supports streamlined operations into 2025 -

... More